Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-03-31
1998-09-01
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 71, 435 72, 530350, 530300, G01N 3353, C07K 704, C07K 14705, C07K 1482
Patent
active
058010050
ABSTRACT:
Methods for the detection, monitoring and treatment of malignancies in which the HER-2
eu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2
eu protein, or detection of immunocomplexes formed between the HER-2
eu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2
eu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
Ioannides, C.G., et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene," Cell. Immunol. 151:225-234, 1993.
Disis, M.L., et al., "Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients With Breast Cancer," Cancer Res. 54:16-20, 1994.
Alper et al., "The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3," Cell Growth & Differentiation 1:591-599, 1990.
Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein," Nature 319:226-230, 1986.
Bishop and Orosz, "Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells," Transplantation 47(4): 671-677, 1989.
Bowen-Pope et al., "Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor recepetors accompany transformation by a wide spectrum of agents," Proc. Natl. Acad. Sci. USA 81: 2396-2400, 1984.
Brooks et al., "Human lymphocyte markers defined by antibodies derived from somatic cell hybrids," Clin. exp. Immunol. 39: 477-485, 1980.
Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," Journal of Biological Chemistry 255(11): 4980-4983, 1980.
Burnette et al., ""Western Blotting": Electropheretic Transfer of Proteins from Sodium Dodecyl Sulfate-Palyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A, "Analytical Biochemistry 112: 195-203, 1981.
Dhut et al., "BCR-ABL and BCR Proteins: Biochemical Characterization and Localization," Leukemia 4(11): 745-750, 1990.
Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351: 290-296, 1991.
Feller and de la Cruz, "Identifying antigenic T-cell sites," Nature 349: 720-721, 1991.
Igelhart et al., "Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer," Cancer Research 50: 6701-6707, 1990.
Ioannides et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," Molecular Carcinogenesis 6: 77-82, 1992.
Kallioniemi et al., "ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization," Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., "c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry," Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4,"Nature 227: 680-685, 1970.
Leitzel et al., "Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer," Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, "The neu (c-erbB-2) Oncogene," Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., "Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence," Journal of Immunology 138(7): 2213-2229, 1987.
McKenzie et al., "Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product," in Vaccines 88, Cold Spring Harbor Laboratory, 1988, pp. 19-23.
Mietzner et al., "Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae," Journal of Experimental Medicine 165: 1041-1057, 1987.
Mori et al., "In Vitro and in vivo Release of Soluble erbB-2 Protein from Human Carcinoma Cells," Japanese Journal of Cancer Research 81: 489-494, 1990.
Paik et al., "Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer," Journal of Clinical Oncology 8(1): 103-112, 1990.
Parker et al., "Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2," Journal of Immunology 149(11): 3580-3587, 1992.
Press et al., "Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues," Oncogene 5: 953-962 , 1990.
Raines and Ross, "Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms," Journal of Biological Chemistry 257(9): 5154-5159, 1982.
Riberdy and Cresswell, "The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class II Antigen Presentation," Journal of Immunology 148(8): 2586-2590, 1992.
Rothbard and Taylor, "A sequence pattern common to T cell epitopes," EMBO Journal 7(1): 93-100, 1988.
Spies et al., "A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway," Nature 348: 744-747, 1990.
Stern et al., "Oncogene Activation of p185.sup.neu Stimulates Tyrosine Phosphorylation In Vivo," Molecular and Cellular Biology 8(9): 3969-3973, 1988.
Trowsdale et al., "Sequence encoded in the class II region of the MHC related to the `ABC` superfamily of transporters," Nature 348: 741-744, 1990.
Wide, L., "Solid Phase Antigen-Antibody Systems," in Radioimmunoassay Methods, Kirkham and Hunter (eds.), 1973, pp. 405-412.
Zabrecky et al., "The Extracellular Domain of p185
eu Is Released from the Surface of Human Breast Carcinoma Cells, SK-BR-3," Journal of Biological Chemistry 266(3): 1716-1720, 1991.
Ioannides et al. FASEBJ. V.6:A 1404 Feb. 26, 1992.
Ioannides, Abstracts Fourth International Conference of Anticancer Research 21-25 Oct. 1992 p. 1870.
Ioannides, Society for Biological Therapy 1992 Annual Meeting, p. 27 Oct. 29-Nov. 1, 1992.
Cheever Martin A.
Disis Mary L.
Hutzell Paula K.
Johnson Nancy A.
University of Washington
LandOfFree
Immune reactivity to HER-2/neu protein for diagnosis of malignan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune reactivity to HER-2/neu protein for diagnosis of malignan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune reactivity to HER-2/neu protein for diagnosis of malignan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-269071